DocuSign President Inhi Suh to step down; severance agreements amended for four other executives

DOCUSIGN, INC.

Inhi Suh, President of Product and Technology, to depart effective Feb 14, 2024; receives $525,000 cash severance plus $525,000 bonus.
COBRA coverage and 12 months equity vesting acceleration provided; additional accelerated vesting if change in control occurs by May 14, 2024.
Amended and restated severance agreements approved for CFO Blake Grayson, Robert Chatwani, James Shaughnessy, and Stephen Shute.
Enhanced severance benefits through Dec 31, 2024: 12 months salary, 100% bonus, COBRA, and equity acceleration for non-CIC terminations.
For CIC-period terminations, all four executives receive 12 months salary, 100% bonus, COBRA, and 100% equity acceleration.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Inhi Cho Suh

President, Product and Technology

DOCU · DOCUSIGN, INC.

Effective: 2024-02-14
Filed: January 16, 2024, 6:59 PM ET

On January 16, 2024, DocuSign, Inc. (the “Company”) announced that Inhi Cho Suh, the Company’s President, Product and Technology, will step down from her position.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Inhi Cho Suh departed as President, Product and Technology at DOCUSIGN, INC..

Action: stepped down
Role: President, Product and Technology

Exact text from the filing

On January 16, 2024, DocuSign, Inc. (the “Company”) announced that Inhi Cho Suh, the Company’s President, Product and Technology, will step down from her position.

View on SEC.gov

DOCUSIGN, INC. filing history →

Source: SEC EDGAR

accession 0001261333-24-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.